Unknown

Dataset Information

0

Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.


ABSTRACT: OBJECTIVE:To compare long-term work loss in methotrexate-refractory early rheumatoid arthritis (RA) patients randomized to the addition of infliximab or conventional combination treatment. METHODS:This study was a multicenter, 2-arm, parallel, randomized, active-controlled, open-label trial. RA patients with <1-year symptom duration were recruited from 15 rheumatology clinics in Sweden between 2002-2005. Patients who did not achieve low disease activity after 3-4 months of methotrexate therapy were randomized to the addition of infliximab or conventional combination treatment with sulfasalazine plus hydroxychloroquine. Yearly sick leave and disability pension days >7 years after randomization were retrieved from nationwide registers kept by the Swedish Social Insurance Agency. RESULTS:Of 210 working-age patients, 109 were randomized to infliximab (mean age 48.4 years, 73% women) and 101 to conventional treatment (mean age 48.7 years, 77% women). The year before randomization, the mean number of annual work days lost was 127 in the infliximab arm and 118 in the conventional treatment group (mean difference 9 [95% confidence interval (95% CI) -23, 39]). Compared to the year before randomization, the mean changes at 7 years were -25 days in the infliximab and -26 days in the conventional treatment group (adjusted mean difference 10 [95% CI -25, 46]). The cumulative mean for work-loss days was 846 in the infliximab group and 701 in the conventional treatment group (adjusted mean difference 104 [95% CI -56, 284]). CONCLUSION:Long-term work loss improved significantly in early RA patients randomized to infliximab plus methotrexate or conventional combination therapy. No difference was detected between strategies, and the level of work-loss days remained twice that observed in the general population.

SUBMITTER: Eriksson JK 

PROVIDER: S-EPMC6767553 | biostudies-literature | 2016 Dec

REPOSITORIES: biostudies-literature

altmetric image

Publications

Infliximab Versus Conventional Combination Treatment and Seven-Year Work Loss in Early Rheumatoid Arthritis: Results of a Randomized Swedish Trial.

Eriksson Jonas K JK   Wallman Johan K JK   Miller Heather H   Petersson Ingemar F IF   Ernestam Sofia S   Vivar Nancy N   van Vollenhoven Ronald F RF   Neovius Martin M  

Arthritis care & research 20161201 12


<h4>Objective</h4>To compare long-term work loss in methotrexate-refractory early rheumatoid arthritis (RA) patients randomized to the addition of infliximab or conventional combination treatment.<h4>Methods</h4>This study was a multicenter, 2-arm, parallel, randomized, active-controlled, open-label trial. RA patients with <1-year symptom duration were recruited from 15 rheumatology clinics in Sweden between 2002-2005. Patients who did not achieve low disease activity after 3-4 months of methotr  ...[more]

Similar Datasets

| S-EPMC4431324 | biostudies-literature
| S-EPMC4168386 | biostudies-literature
2005-11-16 | GSE3592 | GEO
2009-10-02 | GSE12051 | GEO
| S-EPMC1779405 | biostudies-literature
| S-EPMC3003525 | biostudies-literature
| S-EPMC4086877 | biostudies-literature
| S-EPMC2688177 | biostudies-literature
| S-EPMC4695666 | biostudies-literature
| S-EPMC6563948 | biostudies-literature